Peptides for the treatment of COVID-19
AssigneeRush University Medical Center
InventorKalipada Pahan
Life of this patent
Estimating the term…
Abstract
Compositions for inhibiting the binding between ACE2 and SARS-CoV-2 spike S1 are disclosed. Methods of treating COVID-19 are disclosed. Methods of making an in vivo model of COVID-19 are also disclosed.
Claims22
A composition comprising an isolated peptide that inhibits the association between SARS-CoV-2 spike Si of a SARS-CoV-2 variant and Angiotensin Converting Enzyme-2 (ACE-2) without inhibiting the activity of ACE-2, wherein the isolated peptide consists of SEQ ID NO:
- 3, SEQ ID NO:
- 4, SEQ ID NO:
- 5, SEQ ID NO:
- 6, SEQ ID NO:
- 7, or SEQ ID NO:
- 9.
A method of alleviating the symptoms associated with COVID-19, the method comprising administering a first agent to a subject in need thereof, the first agent comprising an isolated peptide that inhibits the association between SARS-CoV-2 spike 51 of a SARS-CoV-2 variant and Angiotensin Converting Enzyme-2 (ACE-2) without inhibiting the activity of ACE-2, wherein the first agent comprises an isolated peptide selected from the group consisting of SEQ ID NO:
- 3, SEQ ID NO:
- 4, SEQ ID NO:
- 5, SEQ ID NO:
- 6, SEQ ID NO:7, and SEQ ID NO:
- 9.
A method of halting the further progression of or worsening of the symptoms associated with COVID-19, the method comprising administering a first agent to a subject in need thereof, the first agent comprising an isolated peptide that inhibits the association between SARS- CoV-2 spike 51 of a SARS-CoV-2 variant and Angiotensin Converting Enzyme-2 (ACE-2) without inhibiting the activity of ACE-2, wherein the first agent comprises an isolated peptide selected from the group consisting of SEQ ID NO:
- 3, SEQ ID NO:
- 4, SEQ ID NO:
- 5, SEQ ID NO:
- 6, SEQ ID NO:
- 7 and SEQ ID NO:
- 9.
Dependencies are inferred from the claim text.